文献速递慢阻肺

血嗜酸性粒细胞与慢阻肺维持治疗反应:FLAME试验数据

Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2017-01-01

FLAME试验预设分析比较茚达特罗/格隆溴铵与沙美特罗/氟替卡松预防慢阻肺急性加重,按血嗜酸性粒细胞百分比和绝对计数分层。结果显示茚达特罗/格隆溴铵在多个嗜酸性粒细胞亚组中显著优于沙美特罗/氟替卡松,且沙美特罗/氟替卡松肺炎发生率更高。

要点

  • 茚达特罗/格隆溴铵在血嗜酸性粒细胞<2%、≥2%、<3%、<5%及<150 cells/μl亚组中预防急性加重均显著优于沙美特罗/氟替卡松。
  • 任何嗜酸性粒细胞切点下沙美特罗/氟替卡松均未优于茚达特罗/格隆溴铵。
  • 沙美特罗/氟替卡松肺炎发生率在<2%和≥2%亚组中均高于茚达特罗/格隆溴铵。

核心结论

  • 在慢阻肺患者中,无论血嗜酸性粒细胞水平如何,茚达特罗/格隆溴铵对急性加重的预防效果优于或类似于沙美特罗/氟替卡松。

研究设计与样本

  • FLAME试验的预设分析,比较每日一次茚达特罗/格隆溴铵110/50 μg与每日两次沙美特罗/氟替卡松50/500 μg。
  • 纳入前一年至少有一次急性加重的慢阻肺患者。

主要发现

  • 茚达特罗/格隆溴铵在<2%、≥2%、<3%、<5%和<150 cells/μl亚组中预防所有严重程度及中重度急性加重均显著优于沙美特罗/氟替卡松。
  • 任何切点下沙美特罗/氟替卡松均未优于茚达特罗/格隆溴铵。
  • 中重度急性加重率未随血嗜酸性粒细胞升高而增加。
  • 沙美特罗/氟替卡松肺炎发生率在<2%和≥2%亚组中均高于茚达特罗/格隆溴铵。

关键数值与推荐

  • 血嗜酸性粒细胞百分比切点:<2%与≥2%、<3%与≥3%、<5%与≥5%。
  • 血嗜酸性粒细胞绝对计数分层:<150 cells/μl、150至<300 cells/μl、≥300 cells/μl。

临床怎么用

  • 对于有急性加重史的慢阻肺患者,选择茚达特罗/格隆溴铵预防急性加重不依赖于血嗜酸性粒细胞水平。

局限性

  • 部分分析为事后分析,需进一步研究验证其他切点和终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Post hoc analyses suggest that blood eosinophils have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management of chronic obstructive pulmonary disease (COPD). OBJECTIVES: We prospectively investigated the value of blood eosinophils as a predictor of responsiveness to an inhaled corticosteroid/long-acting β2-agonist combination versus a long-acting β2-agonist/long-acting muscarinic antagonist combination for exacerbation prevention. METHODS: We conducted prespecified analyses of data from the FLAME (Effect of Indacaterol Glycopyronium vs Fluticasone Salmeterol on COPD Exacerbations) study, which compared once-daily long-acting β2-agonist/long-acting muscarinic antagonist indacaterol/glycopyrronium 110/50 μg with twice-daily long-acting β2-agonist/inhaled corticosteroid salmeterol/fluticasone combination 50/500 μg in patients with one or more exacerbations in the preceding year. Subsequent post hoc analyses were conducted to address further cutoffs and endpoints. MEASUREMENTS AND MAIN RESULTS: We compared treatment efficacy according to blood eosinophil percentage (<2% and ≥2%, <3% and ≥3%, and <5% and ≥5%) and absolute blood eosinophil count (<150 cells/μl, 150 to <300 cells/μl, and ≥300 cells/μl). Indacaterol/glycopyrronium was significantly superior to salmeterol/fluticasone for the prevention of exacerbations (all severities, or moderate or severe) in the <2%, ≥2%, <3%, <5%, and <150 cells/μl subgroups, and at no cutoff was salmeterol/fluticasone superior to indacaterol/glycopyrronium. Furthermore, the rate of moderate or severe exacerbations did not increase with increasing blood eosinophils. The incidence of pneumonia was higher in patients receiving salmeterol/fluticasone than indacaterol/glycopyrronium in both the <2% and ≥2% subgroups. CONCLUSIONS: Our prospective analyses indicate that indacaterol/glycopyrronium provides superior or similar benefits over salmeterol/fluticasone regardless of blood eosinophil levels in patients with COPD. Clinical trial registered with www.clinicaltrials.gov (NCT01782326).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Roche N, Chapman KR, Vogelmeier CF, et al. Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. Am J Respir Crit Care Med. 2017. PMID: 28278391. doi:10.1164/rccm.201701-0193OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。